Obesity as a major risk factor for cancer

G De Pergola, F Silvestris - Journal of obesity, 2013 - Wiley Online Library
The number of cancer cases caused by being obese is estimated to be 20% with the
increased risk of malignancies being influenced by diet, weight change, and body fat …

BRAFV600E: Implications for Carcinogenesis and Molecular Therapy

ER Cantwell-Dorris, JJ O'Leary, OM Sheils - Molecular cancer therapeutics, 2011 - AACR
The mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK)
pathway is frequently mutated in human cancer. This pathway consists of a small GTP …

Biological mechanisms linking obesity and cancer risk: new perspectives

DL Roberts, C Dive, AG Renehan - Annual review of medicine, 2010 - annualreviews.org
Body mass index, as an approximation of body adiposity, is associated with increased risk of
several common and less common malignancies in a sex-and site-specific manner. These …

Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1

JC Ricarte-Filho, M Ryder, DA Chitale, M Rivera… - Cancer research, 2009 - AACR
Patients with poorly differentiated thyroid cancers (PDTC), anaplastic thyroid cancers (ATC),
and radioactive iodine-refractory (RAIR) differentiated thyroid cancers have a high mortality …

Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail

GS Inamdar, SRV Madhunapantula… - Biochemical …, 2010 - Elsevier
The Mitogen Activated Protein Kinase (MAPK) pathway plays a key role in melanoma
development making it an important therapeutic target. In normal cells, the tightly regulated …

MEK inhibitors in the treatment of metastatic melanoma and solid tumors

AM Grimaldi, E Simeone, L Festino, V Vanella… - American journal of …, 2017 - Springer
The mitogen-activated protein kinase (MAPK) cascade is an intracellular signaling pathway
involved in the regulation of cellular proliferation and the survival of tumor cells. Several …

BRAF as therapeutic target in melanoma

C Wellbrock, A Hurlstone - Biochemical pharmacology, 2010 - Elsevier
BRAF is a member of the RAF kinase family, which acts in the ERK/MAP kinase pathway, a
signalling cascade that regulates cellular proliferation, differentiation and survival. Single …

Metastatic melanoma: insights into the evolution of the treatments and future challenges

A Millet, AR Martin, C Ronco, S Rocchi… - Medicinal research …, 2017 - Wiley Online Library
Melanoma is the deadliest form of skin cancer. While associated survival prognosis is good
when diagnosed early, it dramatically drops when melanoma progresses into its metastatic …

Beyond BRAF: where next for melanoma therapy?

IV Fedorenko, GT Gibney, VK Sondak… - British journal of …, 2015 - nature.com
In recent years, melanoma has become a poster-child for the development of oncogene-
directed targeted therapies. This approach, which has been exemplified by the development …

Targeting BRAF for patients with melanoma

HT Arkenau, R Kefford, GV Long - British journal of cancer, 2011 - nature.com
The prognosis of patients with metastatic melanoma is poor and not influenced by systemic
therapy with cytotoxic drugs. New targeted agents directed against the RAS-RAF-MEK-ERK …